Description
LuciTeno 25 MG (Tenofovir Alafenamide) is a nucleotide analog reverse transcriptase inhibitor (NtRTI) an orally bioavailable, phosphonamidate prodrug of tenofovir engineered for targeted intracellular activation in hepatocytes, delivering superior antiviral potency against hepatitis B virus (HBV) DNA polymerase at markedly lower systemic plasma tenofovir exposures than tenofovir disoproxil fumarate (TDF) supplied as film-coated tablets, 25 mg strength, in a 30-tablet bottle/box and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos.
Its active ingredient, tenofovir alafenamide INN (TAF), is converted intracellularly by hepatic cathepsin A and other esterases to tenofovir, which is subsequently phosphorylated to tenofovir diphosphate (TFV-DP) the active metabolite that competitively inhibits HBV DNA polymerase/reverse transcriptase and causes obligate chain termination of the viral DNA strand, halting HBV replication. TAF achieves more than 4-fold higher intracellular TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) and hepatocytes at a 10-fold lower plasma tenofovir exposure than TDF at its approved 300 mg dose enabling equivalent HBV DNA suppression from a 25 mg once-daily dose with significantly reduced renal tubular toxicity and improved preservation of bone mineral density.
In the pivotal Phase 3 trials in chronic HBV Study GS-US-320-0108 (HBeAg-negative) and Study GS-US-320-0110 (HBeAg-positive) tenofovir alafenamide 25 mg once daily achieved virologic suppression (HBV DNA <29 IU/mL) in 94% of HBeAg-negative patients at week 48 and 64% of HBeAg-positive patients at week 48, with non-inferiority to TDF demonstrated in both studies, and with significantly better renal biomarkers and bone mineral density outcomes at week 48 and beyond. Searching for LuciTeno 25 MG Tenofovir Alafenamide? Mediaid Pharmacy lists this product across its hepatitis B medicines, antiviral medicines, and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciTeno 25 MG (Tenofovir Alafenamide)
| Brand Name | LuciTeno 25 MG (Tenofovir Alafenamide) |
| Product Name | LuciTeno |
| Generic Name | Tenofovir Alafenamide INN (also referred to as Tenofovir Alafenamide Fumarate; abbreviated TAF) |
| Drug Class | Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI); Phosphonamidate Prodrug of Tenofovir; HBV DNA Polymerase Inhibitor; Antiviral Agent for Chronic Hepatitis B Virus (HBV) Infection; Nucleos(t)ide Analog (NA); Hepatitis B Treatment Agent |
| Formulation | Film-Coated Tablet (Oral) |
| Available Strength | 25 mg per tablet |
| Available Pack Size | 30 Tablets per Bottle/Box |
| Recommended Dose | Chronic Hepatitis B (adults and pediatric patients ≥12 years, ≥35 kg): 25 mg orally once daily with food (1× LuciTeno 25 MG film-coated tablet once daily). Administer LuciTeno at the same time each day. Swallow tablets whole with food; do not crush or chew. Co-administration with P-gp/CYP3A inducers (e.g., rifampin, carbamazepine): avoid concurrent use these agents significantly reduce tenofovir alafenamide plasma exposure and may lead to loss of virologic suppression. |
| Primary Indication | Chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 12 years and older weighing at least 35 kg with compensated liver disease. LuciTeno 25 MG (Tenofovir Alafenamide) is not recommended for patients with decompensated hepatic disease (Child-Pugh B or C). Always consult the full prescribing information and the treating hepatologist or infectious disease specialist for complete indication-specific and patient-specific dosing guidance. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brand | Vemlidy® (tenofovir alafenamide 25 mg film-coated tablets, by Gilead Sciences, Inc. approved by the U.S. FDA in November 2016 for chronic hepatitis B virus infection in adults with compensated liver disease). Vemlidy® contains tenofovir alafenamide fumarate INN as the active pharmaceutical ingredient in the same NtRTI drug class. LuciTeno is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (20°C to 25°C); excursions permitted between 15°C and 30°C. Store in the original tightly closed bottle or blister packaging and protect from moisture. Keep out of the reach of children. |
How LuciTeno (Tenofovir Alafenamide) Works: Targeted Intracellular Prodrug Activation and HBV DNA Polymerase Inhibition with an Improved Renal and Bone Safety Profile Over TDF
Tenofovir alafenamide INN (TAF) is an orally bioavailable phosphonamidate prodrug of tenofovir a nucleotide analog structurally related to the endogenous nucleotide deoxyadenosine 5′-monophosphate. Chronic hepatitis B virus (HBV) infection is driven by continuous intrahepatic replication of HBV, a partially double-stranded DNA virus whose replication cycle depends on the reverse transcription of a pregenomic RNA (pgRNA) intermediate by the viral HBV DNA polymerase, which possesses both DNA-directed DNA polymerase and RNA-directed DNA polymerase (reverse transcriptase) activities. Uncontrolled viral replication sustains intrahepatic inflammation, progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) the clinical endpoints antiviral suppression is designed to prevent.
TAF is absorbed after oral administration and transported into hepatocytes via plasma membrane transporters; once intracellular, cathepsin A (CatA) and other serine esterases hydrolyze the phosphonamidate moiety of TAF to release tenofovir inside the hepatocyte. Tenofovir is then sequentially phosphorylated by cellular kinases to its active metabolite, tenofovir diphosphate (TFV-DP), which competitively inhibits HBV DNA polymerase by competing with the natural substrate deoxyadenosine 5′-triphosphate (dATP). Incorporation of TFV-DP into the nascent viral DNA strand causes obligate chain termination halting HBV replication at the level of reverse transcription with no clinically relevant activity against human mitochondrial DNA polymerase gamma at therapeutic concentrations.
The pharmacological advance of TAF over TDF lies in its prodrug design: because TAF is stable in plasma and is selectively activated intracellularly in hepatocytes and lymphocytes, it achieves more than 4-fold higher TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) and hepatocytes at a 25 mg once-daily dose compared to the concentrations produced by TDF at its 300 mg once-daily dose with a 10-fold lower systemic plasma tenofovir exposure. Lower plasma tenofovir exposure directly reduces renal proximal tubule cell uptake of tenofovir via OAT1/OAT3 transporters the mechanistic basis for TDF’s dose-limiting nephrotoxicity (Fanconi syndrome, renal tubular acidosis, proximal tubulopathy) and reduces tenofovir-mediated inhibition of mitochondrial DNA polymerase in bone-remodeling osteoblasts, which underlies TDF’s clinically significant reductions in bone mineral density.
In the Phase 3 pivotal trials, patients on TAF 25 mg showed statistically significantly smaller declines in eGFR, urine β2-microglobulin-to-creatinine ratio, and retinol-binding protein-to-creatinine ratio all markers of renal tubular function and significantly smaller reductions in lumbar spine and hip bone mineral density compared to TDF at weeks 48, 96, and 144. Pharmacokinetically, TAF reaches peak plasma concentrations (Tmax) within approximately 0.5 hours after oral administration; food increases TAF AUC by approximately 65%, necessitating administration with food. TAF is metabolized intracellularly to tenofovir; plasma TAF is eliminated rapidly with a mean plasma half-life of approximately 0.51 hours, while the intracellular half-life of TFV-DP in PBMCs is approximately 150 hours supporting the once-daily dosing schedule with sustained antiviral activity. TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); co-administration with P-gp inducers (including rifampin, carbamazepine, and St. John’s Wort) significantly reduces TAF plasma concentrations and must be avoided. For the complete range of hepatitis B antiviral medicines available at Mediaid Pharmacy, visit the hepatitis B medicines collection.
LuciTeno 25 MG (Tenofovir Alafenamide): Indications, Dosing, and Key Safety Information
| Approved Indication | Chronic Hepatitis B Virus (HBV) Infection: LuciTeno 25 MG (Tenofovir Alafenamide) is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 12 years and older weighing at least 35 kg with compensated liver disease. LuciTeno is not indicated for decompensated hepatic disease (Child-Pugh B or C). |
| Recommended Dose | Chronic HBV (adults and pediatric patients ≥12 years, ≥35 kg): 25 mg orally once daily with food (1× LuciTeno 25 MG film-coated tablet once daily). Food is required for adequate TAF absorption administration without food reduces tenofovir alafenamide bioavailability. Swallow LuciTeno tablets whole with water; do not crush, split, or chew. Administer LuciTeno at the same time each day to maintain consistent plasma levels and support adherence. |
| Dose Modification | No dose adjustment is required for mild or moderate renal impairment (creatinine clearance [CrCl] ≥30 mL/min) or for hemodialysis patients (administer LuciTeno after hemodialysis on dialysis days). LuciTeno 25 MG is not recommended for patients with CrCl <15 mL/min who are not receiving hemodialysis, due to insufficient pharmacokinetic data. No dose adjustment is required for mild or moderate hepatic impairment (Child-Pugh A or B); LuciTeno is not recommended in patients with decompensated liver disease (Child-Pugh C). Co-administration with P-gp inducers or strong CYP3A inducers should be avoided rather than managed with dose adjustment, as TAF plasma exposures are reduced to an extent that cannot be corrected within the approved dosing range. |
| Missed Dose | If a LuciTeno dose is missed, take it with food as soon as possible on the same day. If the patient does not remember until the next day, skip the missed dose and resume the regular once-daily dosing schedule. Do not take 2 doses of LuciTeno on the same day to compensate for a missed dose. Maintaining consistent daily dosing without interruption is important to prevent virologic breakthrough and reduce the risk of hepatitis B disease flares. |
| Key Warnings & Precautions | Severe Acute Exacerbation of Hepatitis B on Discontinuation: Severe acute exacerbations of hepatitis B including cases resulting in liver failure and death have been reported in patients who have discontinued anti-HBV therapies, including TAF. Hepatic function must be monitored closely with both clinical and laboratory follow-up for at least several months after stopping LuciTeno in HBV-infected patients. Resuming hepatitis B therapy may be warranted. Never discontinue LuciTeno without explicit guidance from the treating hepatologist.
Risk of HIV-1 Drug Resistance in Undiagnosed or Untreated HIV-1 Co-Infection: LuciTeno 25 MG (Tenofovir Alafenamide) is not indicated for the treatment of HIV-1 infection. Patients with chronic HBV infection should be tested for HIV-1 before initiating LuciTeno. If LuciTeno is used in a patient with undiagnosed HIV-1 infection, the TAF component as a monotherapy may lead to HIV resistance development. Use an appropriate fully suppressive antiretroviral combination regimen in patients co-infected with HIV-1 and HBV. Lactic Acidosis / Severe Hepatomegaly with Steatosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside/nucleotide analog use, including tenofovir-containing products. Discontinue LuciTeno if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop. New-Onset or Worsening Renal Impairment: Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported with tenofovir-containing products, more commonly with TDF than TAF. Calculate estimated GFR (eGFR), urine glucose, and urine protein before initiating LuciTeno and monitor during therapy. In patients at risk for renal impairment, additional monitoring of serum phosphate and urine glucose is advisable. Lipid Changes: Increases in total cholesterol, LDL cholesterol, and HDL cholesterol have been observed with TAF versus TDF in clinical trials. Monitor lipid profiles at baseline and periodically during LuciTeno therapy; manage dyslipidemia per current clinical guidelines. |
| Common Adverse Reactions (≥5%) | In the Phase 3 clinical trials, the most common adverse reactions occurring in 5% or more of tenofovir alafenamide-treated patients include headache, abdominal pain, fatigue, cough, nausea, and back pain. LuciTeno (Tenofovir Alafenamide) is generally well tolerated, with a markedly lower rate of clinically significant renal adverse reactions and bone mineral density reduction compared to TDF the principal safety advantages established in the comparative Phase 3 trial data. Lipid elevations (total cholesterol, LDL) have been more commonly observed with TAF than TDF and should be monitored and managed per standard lipid guidelines during LuciTeno treatment. |
| Drug Interactions | Tenofovir alafenamide is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and CYP3A. P-gp/CYP3A inducers including rifampin, rifabutin, rifapentine, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, and St. John’s Wort significantly reduce TAF plasma exposure; avoid co-administration with LuciTeno. P-gp inhibitors such as certain antiretroviral pharmacokinetic boosters (cobicistat, ritonavir) used in HIV fixed-dose combinations that include TAF increase TAF concentrations; LuciTeno 25 MG as a standalone HBV agent is not co-formulated with these boosters. TAF does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 and does not interact with drugs metabolized by these pathways. Disclose all medications, herbal supplements, and anti-tuberculosis agents to the treating hepatologist or infectious disease specialist before initiating LuciTeno 25 MG (Tenofovir Alafenamide). |
| Renal Impairment | No dose adjustment is required for patients with mild renal impairment (CrCl 60–89 mL/min), moderate renal impairment (CrCl 30–59 mL/min), or for patients on hemodialysis (administer after the dialysis session on dialysis days). LuciTeno 25 MG is not recommended for patients with severe renal impairment (CrCl 15–29 mL/min) or end-stage renal disease (CrCl <15 mL/min) not receiving hemodialysis, due to insufficient pharmacokinetic and safety data in these populations. Consult the full prescribing information and the treating nephrologist and hepatologist for individualized guidance. |
| Pregnancy & Lactation | Available data from the Antiretroviral Pregnancy Registry on TAF use in pregnancy are limited. Animal studies with tenofovir at high exposures showed no adverse developmental effects, but human data are insufficient to confirm safety. LuciTeno should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus; the treating hepatologist must conduct a careful benefit-risk assessment. Untreated maternal hepatitis B carries significant risks of vertical HBV transmission during delivery this must be weighed against the limited pregnancy safety data for TAF specifically. Tenofovir is present in human breast milk; breastfeeding is not recommended during LuciTeno treatment, primarily due to the potential for HIV-1 transmission in HIV co-infected mothers. Consult the treating specialist before initiating, continuing, or discontinuing LuciTeno in patients who are pregnant or breastfeeding. |
Who Should Use LuciTeno 25 MG (Tenofovir Alafenamide)?
LuciTeno 25 MG (Tenofovir Alafenamide) is indicated for adults and pediatric patients aged 12 years and older weighing at least 35 kg with chronic hepatitis B virus (HBV) infection and compensated liver disease the population established by the pivotal Phase 3 studies GS-US-320-0108 and GS-US-320-0110, which enrolled both HBeAg-negative and HBeAg-positive patients across a broad range of baseline HBV DNA levels, ALT profiles, and prior treatment histories. Chronic HBV infection affects an estimated 296 million people worldwide and is the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) globally; long-term antiviral suppression with potent nucleos(t)ide analogs (NAs) such as TAF is the cornerstone of preventing these outcomes.
HBeAg-negative chronic HBV patients who represent the majority of chronic HBV patients globally, particularly in Asian and African regions with high endemic HBV prevalence achieved virologic suppression (HBV DNA <29 IU/mL) in 94% of TAF-treated patients at week 48 in Study GS-US-320-0108, with response rates maintained at 90% through week 96. HBeAg-negative patients typically require long-term or indefinite antiviral therapy without a finite treatment endpoint, making TAF’s superior renal and bone safety profile over TDF particularly clinically relevant for the duration of lifelong treatment. HBeAg-positive chronic HBV patients who are more common in patients with perinatally acquired infection and in younger adults achieved HBV DNA <29 IU/mL in 64% of TAF patients at week 48, increasing to 73% at week 96, with HBeAg seroconversion occurring in 10% at week 48 in Study GS-US-320-0110.
Patients with pre-existing renal risk factors or reduced bone mineral density are particularly well-suited for LuciTeno over TDF-based regimens: in both Phase 3 trials, TAF demonstrated significantly less eGFR decline and significantly greater preservation of lumbar spine and total hip bone mineral density through week 144 compared to TDF differences that are clinically meaningful for patients with baseline chronic kidney disease, osteopenia, osteoporosis, or concomitant nephrotoxic agents. LuciTeno is appropriate for both treatment-naïve patients initiating antiviral therapy and treatment-experienced patients switching from TDF or other HBV antivirals in whom better renal or bone tolerability is required. LuciTeno is not appropriate for patients with decompensated liver disease (Child-Pugh B or C), patients with HBV/HIV-1 co-infection not on a fully suppressive HIV regimen, patients on unavoidable P-gp or CYP3A inducers, or pediatric patients weighing less than 35 kg. Hepatology centers sourcing LuciTeno alongside complementary agents for viral hepatitis management can browse the Mediaid Pharmacy chronic hepatitis B virus treatment medicines and antiviral medicines portfolios for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciTeno 25 MG (Tenofovir Alafenamide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty antiviral, hepatology, and targeted oncology medicines with worldwide shipping to patients, hepatology clinics, liver disease centers, infectious disease hospitals, and international distributors across all regions. LuciTeno 25 MG (Tenofovir Alafenamide), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as film-coated tablets 25 mg per tablet, 30 tablets per bottle/box with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The 30-tablet monthly pack aligns precisely with the once-daily dosing schedule of tenofovir alafenamide (25 mg once daily), providing hepatology pharmacies, outpatient liver clinics, and individual patients with a single-box monthly supply that simplifies dispensing, refill management, and procurement planning.
Hepatology centers treating chronic HBV patients; hospital pharmacy teams; infectious disease clinics managing HBV in HIV co-infected patients; international distributors; and individual chronic HBV patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciTeno Tenofovir Alafenamide stock availability, current pricing, and international delivery timelines. Procurement teams co-sourcing LuciTeno with other antiviral or hepatology medicines can browse the complete Mediaid Pharmacy antiviral medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciTeno 25 MG (Tenofovir Alafenamide) from Mediaid Pharmacy?
LuciTeno 25 MG (Tenofovir Alafenamide) provides hepatologists, infectious disease specialists, and liver disease programs with a next-generation, pharmacologically optimized NtRTI for chronic HBV that achieves equivalent virologic suppression to TDF with a substantially improved renal and bone safety profile advantages that are directly relevant for the long-term, often lifelong antiviral therapy that chronic HBV management requires. The Phase 3 registration program demonstrated that TAF 25 mg once daily achieved virologic suppression in 94% of HBeAg-negative patients and 64% of HBeAg-positive patients at week 48 rates statistically non-inferior to TDF 300 mg once daily while simultaneously producing significantly smaller declines in eGFR, significantly lower urine markers of renal proximal tubule injury (urine β2-microglobulin-to-creatinine ratio, urine retinol-binding protein-to-creatinine ratio), and significantly smaller reductions in lumbar spine and total hip bone mineral density at weeks 48, 96, and 144 across both trials.
These safety advantages are not marginal: in Study GS-US-320-0108, lumbar spine bone mineral density changed by −0.10% with TAF versus −2.51% with TDF at week 48 a greater than 2.4 percentage-point difference in bone preservation that compounds over years of continuous treatment and is clinically meaningful for the substantial proportion of chronic HBV patients with baseline osteopenia, reduced eGFR, or concomitant nephrotoxic medications. The high resistance barrier of tenofovir alafenamide is equally important for long-term treatment confidence: in the Phase 3 trials through week 96, no resistance substitutions in the HBV polymerase/reverse transcriptase gene were detected in viremic patients on TAF consistent with the broad clinical experience of TDF and establishing TAF’s utility as a durable, resistance-proof backbone for chronic HBV management. The simple once-daily oral dose of LuciTeno 25 mg once daily with food, from a 30-tablet monthly bottle/box requires no weight-based titration, no dose escalation, and no renal dose adjustment above CrCl 15 mL/min, reducing the prescribing and dispensing complexity that hepatology pharmacies manage in outpatient liver clinics.
LuciTeno is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Lucius Pharmaceuticals antiviral and hepatology medicines, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the hepatitis B medicines portfolio, and contact the team for a personalized quotation.
Frequently Asked Questions About LuciTeno 25 MG (Tenofovir Alafenamide)
What is LuciTeno 25 MG (Tenofovir Alafenamide) used for?
LuciTeno 25 MG (Tenofovir Alafenamide) is a nucleotide analog reverse transcriptase inhibitor (NtRTI) used for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 12 years and older weighing at least 35 kg with compensated liver disease. Tenofovir alafenamide (TAF) is a phosphonamidate prodrug converted intracellularly to tenofovir diphosphate, which competitively inhibits HBV DNA polymerase/reverse transcriptase and causes chain termination of viral DNA replication. LuciTeno is not indicated for decompensated liver disease and is not an approved treatment for HIV-1 infection as a monotherapy. The originator brand for tenofovir alafenamide 25 mg for chronic HBV is Vemlidy® (Gilead Sciences, Inc.), approved by the U.S. FDA in November 2016. LuciTeno, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping.
What is the generic name of LuciTeno?
The generic name of LuciTeno is tenofovir alafenamide INN also referred to as tenofovir alafenamide fumarate (TAF). LuciTeno is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for tenofovir alafenamide manufactured in Laos. LuciTeno is formulated as film-coated tablets, 25 mg strength, supplied in a 30-tablet bottle/box corresponding to a standard 30-day monthly treatment supply at the approved once-daily dose. The originator reference brand is Vemlidy® (Gilead Sciences, Inc.). Mediaid Pharmacy distributes LuciTeno globally with worldwide shipping to patients, hepatology clinics, liver disease hospitals, and specialist centers.
What is the difference between LuciTeno (Tenofovir Alafenamide) and Vemlidy (Tenofovir Alafenamide)?
LuciTeno and Vemlidy® both contain tenofovir alafenamide (TAF) INN as the active pharmaceutical ingredient and share the same NtRTI mechanism of action, the same approved indication (chronic HBV infection in compensated liver disease), and the same 25 mg once-daily oral dosing schedule with food. Vemlidy® is the originator brand developed by Gilead Sciences, Inc., approved by the U.S. FDA in November 2016, and marketed in the United States and other major markets. LuciTeno is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy for international procurement by hepatology clinics and patients in regions where Vemlidy® may be unavailable or cost-prohibitive. For the full range of hepatitis B treatment medicines at Mediaid Pharmacy, explore the complete HBV medicines collection.
What is the difference between Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF)?
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are both prodrugs of tenofovir that inhibit HBV DNA polymerase through the same active metabolite, tenofovir diphosphate (TFV-DP). The key pharmacological difference is intracellular drug delivery efficiency: TAF is a phosphonamidate prodrug that is selectively activated inside hepatocytes, achieving more than 4-fold higher intracellular TFV-DP concentrations at a 25 mg once-daily dose compared to TDF’s 300 mg once-daily dose, with a 10-fold lower systemic plasma tenofovir exposure. Lower plasma tenofovir exposure with TAF directly reduces tenofovir uptake into renal proximal tubule cells and bone-remodeling osteoblasts the cells responsible for TDF’s dose-limiting renal toxicity (Fanconi syndrome, proximal tubulopathy) and bone mineral density reduction. In comparative Phase 3 trials (GS-US-320-0108 and GS-US-320-0110), TAF produced statistically significantly smaller declines in eGFR and significantly greater preservation of lumbar spine bone mineral density compared to TDF at weeks 48, 96, and 144, with equivalent HBV DNA suppression rates establishing TAF as the preferred NtRTI for patients with renal risk factors, reduced bone mineral density, or projected long-term therapy duration.
How is LuciTeno 25 MG (Tenofovir Alafenamide) administered?
LuciTeno (Tenofovir Alafenamide) is administered orally once daily at a fixed dose of 25 mg with food. Taking LuciTeno with food is required food increases tenofovir alafenamide AUC by approximately 65% and is necessary for adequate systemic exposure. Swallow LuciTeno film-coated tablets whole with water; do not crush, split, or chew the tablets. Take LuciTeno at the same time each day to support consistent plasma levels and long-term adherence. If a dose is missed, take it with food as soon as remembered on the same day; if the patient recalls only the next day, skip the missed dose and resume the regular schedule. Do not take 2 doses on the same day. Do not discontinue LuciTeno without guidance from the treating hepatologist abrupt discontinuation may trigger a severe acute hepatitis B flare. Avoid co-administration with P-gp/CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John’s Wort, which significantly reduce TAF exposure and may lead to loss of HBV virologic control.
What are the side effects of LuciTeno 25 MG (Tenofovir Alafenamide)?
LuciTeno (Tenofovir Alafenamide) is generally well tolerated. The most common adverse reactions occurring in 5% or more of patients in the Phase 3 HBV trials include headache, abdominal pain, fatigue, cough, nausea, and back pain. Unlike tenofovir disoproxil fumarate (TDF), tenofovir alafenamide has demonstrated significantly lower rates of clinically meaningful renal adverse events (eGFR decline, proximal tubulopathy, Fanconi syndrome) and significantly better preservation of bone mineral density in Phase 3 comparative studies the most important clinical safety differentiation for long-term HBV therapy. Lipid elevations specifically increases in total cholesterol, LDL cholesterol, and HDL cholesterol have been more commonly observed with TAF than with TDF; monitor and manage lipid profiles per standard clinical guidelines during LuciTeno treatment. Lactic acidosis and severe hepatomegaly with steatosis, though rare, have been reported with nucleoside/nucleotide analogs discontinue LuciTeno if these are suspected. Always discuss the complete safety profile, individual patient risk factors, and monitoring schedule with the treating hepatologist before and throughout LuciTeno treatment.
How effective is Tenofovir Alafenamide (LuciTeno) for chronic hepatitis B?
Tenofovir alafenamide has demonstrated robust and durable antiviral efficacy in the two pivotal Phase 3 trials in chronic HBV. In Study GS-US-320-0108 (HBeAg-negative chronic HBV, 426 patients receiving TAF), 94% of TAF-treated patients achieved HBV DNA <29 IU/mL at week 48 (versus 93% with TDF; non-inferiority p<0.001), with response rates maintained at 90% at week 96. In Study GS-US-320-0110 (HBeAg-positive chronic HBV, 581 patients receiving TAF), 64% of TAF-treated patients achieved HBV DNA <29 IU/mL at week 48 (versus 67% with TDF; non-inferiority confirmed), with rates increasing to 73% at week 96. Critically, through week 96 in both studies, no resistance substitutions in the HBV polymerase reverse transcriptase gene were detected in patients receiving TAF establishing tenofovir alafenamide’s high resistance barrier for long-term chronic HBV management. LuciTeno delivers the same active ingredient tenofovir alafenamide INN at the same approved dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete antiviral medicines range at Mediaid Pharmacy, visit the antiviral medicines collection.
Is LuciTeno 25 MG (Tenofovir Alafenamide) safe during pregnancy or while breastfeeding?
The safety of tenofovir alafenamide (TAF) during human pregnancy has not been fully established. Available pregnancy registry data are limited; animal reproduction studies with tenofovir at high doses did not show evidence of fetal harm, but these findings cannot be reliably extrapolated to human use at therapeutic doses. LuciTeno should be used during pregnancy only when the treating hepatologist determines that the benefit to the mother clearly outweighs the potential risk to the fetus for example, in women with high HBV viral loads where maternal treatment is needed to prevent vertical HBV transmission to the newborn. In clinical practice, the decision to use TAF in pregnancy must account for the consequences of untreated active hepatitis B, the availability of alternative HBV antivirals with more established pregnancy safety data (such as TDF or telbivudine), and the patient’s individual viral and hepatic status. Breastfeeding is not recommended during LuciTeno treatment, particularly in HIV-co-infected mothers, due to risk of HIV transmission via breast milk. Consult the treating hepatologist, obstetrician, and infectious disease specialist before initiating, continuing, or discontinuing LuciTeno in patients who are pregnant, planning a pregnancy, or breastfeeding.
Can I order LuciTeno 25 MG (Tenofovir Alafenamide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciTeno 25 MG (Tenofovir Alafenamide) to patients, hepatology clinics, liver disease hospitals, infectious disease centers, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciTeno 25 MG (Tenofovir Alafenamide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Reviews
There are no reviews yet.